Navigation Links
Synteract and Harrison Clinical Research Close Deal to Form Multinational CRO

SAN DIEGO, Mar. 1, 2013 /PRNewswire/ -- Synteract, a leading full-service contract research organization (CRO) and portfolio company of San Francisco-based Gryphon Investors, has completed its acquisition of Harrison Clinical Research ("HCR") to form a new multinational CRO – SynteractHCR. The company will have its corporate headquarters in San Diego County. Wendel Barr will lead SynteractHCR as CEO. Dr. Francisco Harrison, formerly HCR's chairman and founder, will remain a senior member of the executive team and become a member of the Board of Directors.  The existing management stays in place, with former Synteract COO Stewart Bieler becoming president of U.S. operations and former HCR CEO Benedikt van Nieuwenhove becoming president of European operations for SynteractHCR.


The merger of the companies will make SynteractHCR a top tier, global CRO and provide additional resources and scale to support large, later phase programs:

  • Geographic Footprint — The combined company will have offices in 16 countries with operations in both Western and Eastern Europe, Israel and South America, as well as the U.S.  In addition to its headquarters in San Diego, California, SynteractHCR's U.S.presence will include two offices on the East coast in Research Triangle Park, North Carolina and Princeton, New Jersey, reflecting coverage of three important biopharmaceutical hubs. This expanded presence will allow the company to offer strong international and regional clinical trial support to clients throughout the world. SynteractHCR also maintains a clinical in-patient unit in Germany that will help enlist and treat trial patients, as well as a clinical research training center in Belgium to assist internal and external professionals.
  • Longstanding Experience and Talent — SynteractHCR has exceptionally strong, full-service clinical development expertise with a staff of more than 800. Typical employee tenure at the company is greater than five years. Employees have a lower-than-average turnover rate compared to the industry.
  • Client Loyalty and Repeat Business — A strong tradition of customer service excellence combined with a high regard for trust and transparency are cornerstones of ongoing client relationships, resulting in a high percentage of repeat and referral business. 
  • Reinforced Therapeutic Breadth — Both organizations have a complementary heritage of managing Phase I-IV clinical trials across multiple therapeutic areas, much of which strategically aligns with the largest areas of clinical R&D investment, including oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. 

SynteractHCR is focused on enabling and supporting the innovation and development of better therapies in healthcare. A continued directive of the new combined company will be to maintain a strong connection with emerging to midsize biopharmaceutical companies through which a consultative approach and strong clinical development expertise provide the foundation of its customer relationships.

"Our longstanding drug development expertise allows us to form a new global leader with enhanced scale and therapeutic breadth, but with the personal approach that we have always taken to working with clients," said CEO Wendel Barr . "We will provide a continuum of service that allows us to work with clients throughout the entire development life cycle, from emerging products through post-marketing, and will bring technology efficiencies to the company that will help to take time and cost out of drug development."

SynteractHCR is a portfolio company of Gryphon Investors, a San Francisco-based premier middle market private equity firm, which was the lead financial partner in the acquisition.  Fairmount Partners provided financial advice to Synteract, while KPMG International provided financial advice to HCR. Terms of the transaction were not disclosed.

The new company will unveil its new brand identity and messaging at the DIA EuroMeeting in Amsterdam, from March 4-6, 2013, in booth 616. In addition, Andrei Kravchenko , MD, PhD, Head of Office, Ukraine, will participate as session chair on Tuesday, March 5th at 2-3:30 p.m. CET on "Enhancing Clinical Research Effectiveness."

About SynteractHCR (
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, SynteractHCR delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.

Beth Walsh

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Synteract Appoints Keith Kelson as Chief Financial Officer and Member of Executive Council and Philip Doren, Ph.D., as Vice President, Biometrics
2. Synteract Leadership to Provide Insights at Industry Events on Both West and East Coasts
3. Synteract Senior Director Olivia Montano Honored as One of the PharmaVOICE 100
4. Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference
5. Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure
6. Citiustech Announces Launch of Bi-Clinical Cloud and App-Based Architecture
7. Elsevier Showcases Predictive Analytic and Clinical Integration Solutions at HIMSS13
8. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
9. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
10. Elekta Focuses on Clinical Workflows with MOSAIQ Oncology Information Management System at HIMSS13 Meeting
11. Cardica Updates Enrollment Progress In European Clinical Trial
Post Your Comments:
(Date:10/13/2015)...  Synapse Biomedical Inc. ( ) reported today ... the use of the NeuRx ® Diaphragm Pacing ... the United States and ... The PAS study group met their initial enrollment goal ... since expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... , Oct. 13 2015 ... the "US & European markets for Meniscal ... their offering. --> ) has ... European markets for Meniscal Repair - 16 Countries ... Research and Markets ( ) has ...
(Date:10/13/2015)... Research and Markets ( ) has ... Types (Bacteria, Yeast, Mold, Others), Flavors (Herbs & Spices, ... by Region - Forecasts to 2020" report to ... --> The global market for kombucha ... terms of value, the market is projected to reach ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... In an ... utility costs were 36 percent lower per square foot than in 2009. The Williamsport ... cost of heating and cooling has decreased by eight percent. , According to ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have an ... has joined with Global Dental Relief (GDR) to help bring dental care ... SmileCareClub will donate one clinic visit to a child in Kenya. , “When SmileCareClub ...
(Date:10/13/2015)... ... 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value ... without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Seattle and the University of British Columbia found that certain genetic alterations were seen ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):